Studies suggest new breast screening standards | MassDevice.com On Call
May 1, 2012 by MassDevice staff
A pair of studies suggests that women with relatives who have breast cancer or who have dense breast tissue should begin having mammograms every 2 years at age 40, helping settle the uncertainty over how often women should be screened for breast cancer.
MASSDEVICE ON CALL — Two studies published today in the Annals of Internal Medicine could influence the standard of care for breast screening, which was called into question by a U.S. Preventive Services Task Force report in 2009.
That report suggested that annual mammograms might cause more harm than good because of increased false positives leading to unnecessary biopsies and further testing – not to mention considerable anxiety for patients.
- Show paged
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
- Medtech storytelling in the era of comparative effectiveness
- Medical device sales: Wright Medical's pilot program on rep-less sales process worth watching
- Raising an early warning in the ICU: T3
- Staff shakeup underway at Russian medical device regulator
- Heart Rhythm Society 2013 Scientific Session wrap-up
- Physician blogger insights on social media
Navigation
NEWS
Pluristem launches Phase I clinical trial to treat tendonitis with stem cells
Pluristem is seeking clinical proof that stem cell therapy can benefit patients with chronic...
GE Healthcare unveils soft tissue imaging technology
GE Healthcare introduces Mavric SL, a novel magnetic resonance imaging technique for joint...
Hip implants: Johnson & Johnson's DePuy will stop selling metal-on-metal implants
Johnson & Johnson subsidiary DePuy Orthopaedics plans to phase out sales of all of its metal-on-...
Combat Medical Systems wins 1st-of-its kind approval for tourniquet
The FDA approves a novel combat-ready clamp to treat wounds most commonly associated with roadside or...
Vascular Solutions CEO: Boston Scientific's alleged patent infringement 'blatant'
Vascular Solutions CEO Howard Root says alleged infringement by Boston Scientific's Guidezilla "is...
